Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in Hospitalized Heart Failure
NCT02914665Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing 20 mg elamipretide with Placebo (2 arms). Primary endpoint: Change in NT-proBNP at Day 8. Started Oct 2016; status: completed.
02
Drugs
elamipretide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02914665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914665.